Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations imposed by the use of human adenoviruses due to widesp...

Descripció completa

Dades bibliogràfiques
Autors principals:	Folegatti, P, Bellamy, D, Roberts, R, Powlson, J, Edwards, N, Mair, C, Bowyer, G, Poulton, I, Mitton, C, Green, N, Berrie, E, Lawrie, A, Hill, A, Ewer, K, Hermon-Taylor, J, Gilbert, S
Format:	Journal article
Publicat:	MDPI 2019

Ítems similars

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
per: Pedro M. Folegatti, et al.
Publicat: (2019-05-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
per: Zhang, C, et al.
Publicat: (2023)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
per: Sharpe, HR, et al.
Publicat: (2022)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
per: Cheng Zhang, et al.
Publicat: (2023-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
per: Adam Berg, et al.
Publicat: (2021-10-01)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
per: Hannah R. Sharpe, et al.
Publicat: (2022-03-01)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens
per: Antrobus, R, et al.
Publicat: (2014)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
per: Antrobus, R, et al.
Publicat: (2014)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
per: Jinnam Kim, et al.
Publicat: (2023-04-01)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
per: Moreira Folegatti, P
Publicat: (2021)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
per: O'Hara, G, et al.
Publicat: (2012)

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
per: Folegatti, P, et al.
Publicat: (2021)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
per: Ashley C. Beavis, et al.
Publicat: (2023-07-01)

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
per: Folegatti, P, et al.
Publicat: (2021)

Safety and immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults: a dose-escalation, open-label, non-randomised, phase 1b trial
per: Bosaeed, M, et al.
Publicat: (2021)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
per: Charlotte Davis, et al.
Publicat: (2024-06-01)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
per: Dicks, M, et al.
Publicat: (2015)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
per: Edmund G.-T. Wee, et al.
Publicat: (2024-08-01)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
per: Pedro M. Folegatti, et al.
Publicat: (2021-03-01)

Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels
per: Alharbi, N, et al.
Publicat: (2019)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
per: Jer-Hwa Chang, et al.
Publicat: (2022-02-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
per: Hermosilla, E, et al.
Publicat: (2022)

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial
per: Folegatti, PM, et al.
Publicat: (2019)

Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
per: Ting-Yun Lin, et al.
Publicat: (2022-08-01)

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
per: Tamsin Cargill, et al.
Publicat: (2023-11-01)

Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
per: Nawamin Pinpathomrat, et al.
Publicat: (2022-05-01)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
per: Ogbe, A, et al.
Publicat: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
per: Eduardo Hermosilla, et al.
Publicat: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
per: López-Camacho, C, et al.
Publicat: (2020)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
per: César López-Camacho, et al.
Publicat: (2020-06-01)

Is the ChAdOx1 Vaccine Safe and Immunogenic as Prophylactic Measure Against the Lethal Human-Coronaviruses? A Systematic Review
per: Andréia Michelle Alves Cunha de Alcântar, et al.
Publicat: (2023-07-01)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
per: Ane Ogbe, et al.
Publicat: (2022-04-01)

Simian adenoviruses as vaccine vectors
per: Morris, S, et al.
Publicat: (2016)

Simian adenoviruses as vaccine vectors
per: Morris, S, et al.
Publicat: (2016)

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand
per: Kriangkrai Chawansuntati, et al.
Publicat: (2024-06-01)

Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses
per: Alex Olvera, et al.
Publicat: (2024-03-01)

Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
per: Nawamin Pinpathomrat, et al.
Publicat: (2022-09-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured onthe AGE1.CR.pIX Avian Cell Line
per: Folegatti, P, et al.
Publicat: (2019)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
per: Folegatti, PM, et al.
Publicat: (2020)

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
per: Barrett, J, et al.
Publicat: (2020)